NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Immutep Limited (F: YP1A)

 
YP1A Technical Analysis
5
As on 2nd Mar 2026 YP1A STOCK Price closed @ 2.28 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 1.58 & Strong Buy for SHORT-TERM with Stoploss of 1.87 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

YP1ASTOCK Price

Open 2.28 Change Price %
High 2.28 1 Day 0.04 1.79
Low 2.28 1 Week -0.02 -0.87
Close 2.28 1 Month -0.30 -11.63
Volume 6300 1 Year 0.43 23.24
52 Week High 2.64 | 52 Week Low 1.17
 
F Germany Most Active Stocks
IMU 0.10 -99.65%
IMU 0.10 -99.65%
IMU 0.10 -99.65%
IMU 0.10 -99.65%
IMU 0.10 -99.65%
TEF 3.84 -0.52%
TEF 3.84 -0.52%
WHL 5150.00 -0.44%
WDI 0.05 -37.50%
WDI 0.05 -37.50%
 
F Germany Top Gainers Stocks
JYR 1000000.00 10000000000.00%
JYR 1000000.00 10000000000.00%
LAW 1000000.00 5000000000.00%
LAW 1000000.00 5000000000.00%
LAW 1000000.00 5000000000.00%
LAW 1000000.00 5000000000.00%
NT5 1000000.00 4629529.50%
NT5 1000000.00 4629529.50%
NT5 1000000.00 4629529.50%
30T 1000000.00 3759298.50%
 
F Germany Top Losers Stocks
6CI 0.00 -100.00%
6CI 0.00 -100.00%
CGG 0.00 -100.00%
CGG 0.00 -100.00%
CGG 0.00 -100.00%
P2I 0.00 -100.00%
P2I 0.00 -100.00%
PVGB 0.00 -100.00%
TCU 0.00 -100.00%
TCU 0.00 -100.00%
 
 
YP1A
Daily Charts
YP1A
Intraday Charts
Whats New @
Bazaartrend
YP1A
Free Analysis
 
YP1A Important Levels Intraday
RESISTANCE2.28
RESISTANCE2.28
RESISTANCE2.28
RESISTANCE2.28
RESISTANCE2.28
RESISTANCE2.28
RESISTANCE2.28
RESISTANCE2.28
 
YP1A Forecast March 2026
4th UP Forecast3.17
3rd UP Forecast2.88
2nd UP Forecast2.71
1st UP Forecast2.53
1st DOWN Forecast2.03
2nd DOWN Forecast1.85
3rd DOWN Forecast1.68
4th DOWN Forecast1.39
 
YP1A Weekly Forecast
4th UP Forecast3.17
3rd UP Forecast2.88
2nd UP Forecast2.71
1st UP Forecast2.53
1st DOWN Forecast2.03
2nd DOWN Forecast1.85
3rd DOWN Forecast1.68
4th DOWN Forecast1.39
 
YP1A Forecast2026
4th UP Forecast5.65
3rd UP Forecast4.57
2nd UP Forecast3.9
1st UP Forecast3.23
1st DOWN Forecast1.33
2nd DOWN Forecast0.66
3rd DOWN Forecast-0.01
4th DOWN Forecast-1.09
 
 
YP1A Other Details
Segment EQ
Market Capital 293773568.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
YP1A Address
YP1A
 
YP1A Latest News
 
Your Comments and Response on Immutep Limited
 
YP1A Business Profile
Immutep Limited, a biotech company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its principal product candidate is IMP321, also known as ?eftilagimod alpha' or ?efti', which is a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer termed AIPAC; and is being evaluated as a combination therapy in head and neck squamous cell carcinoma and non-small cell lung carcinoma in a Phase II clinical trial called TACTI-002 and an investigator initiated Phase I trial called INSIGHT in advanced solid tumors. Its other products include IMP761, IMP701 and IMP731, all of which are related to lymphocyte activation gene 3, a gene linked to the regulation of T cells in immune responses. It has partnerships with GlaxoSmithKline, Novartis, CYTLIMIC Inc., INSIGHT, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia. Address: 95 Pitt Street, Sydney, NSW, Australia, 2000
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service